# Special Drug Use Surveillance of Irribow in Female Patients

> **NCT02612649** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 793 (actual)

## Conditions studied

- Diarrhea-predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** Ramosetron

## Key facts

- **NCT ID:** NCT02612649
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-01
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-03-31
- **Target enrollment:** 793 (ACTUAL)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612649, "Special Drug Use Surveillance of Irribow in Female Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02612649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*